The majority of kidney transplant centres routinely use antibody induction therapy, such as monoclonal interleukin 2 receptor antibodies (IL2RA) or T-lymphocyte depleting agents [most commonly rabbit-derived antithymocyte globulin (rATG)] [1] [2] [3] , as part of their treatment regimen. The rationale for this strategy is based on randomized trials performed in the 1990s and early 2000s, in which these agents were shown to reduce acute rejection (AR) rates. Consequently, the 2009 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for the care of kidney transplant patients strongly recommended (Grade 1B) routine use of IL2RA as a first-line therapy, and suggested lymphocyte-depleting agents be reserved for high-risk cases (Grade 2B) [1] .
Today, however, the routine use of induction therapy is debatable, as we argued recently [4] . In fact, the clinical trials on which the 2009 KDIGO guidelines based their recommendations mostly used outdated maintenance regimens. Current triple immunosuppressive therapy with steroids, tacrolimus (Tac) and mycophenolate (MPA) results in a much lower incidence of AR than observed with older therapeutic regimens and, consequently, it is highly likely that induction therapy is now redundant in transplant recipients with a standard immunological risk profile [3, [5] [6] [7] [8] . Induction therapy is clearly more important in patients with higher immunological risk, in whom rATG has been shown to be superior to IL2RA in preventing AR [9] [10] [11] [12] . We therefore questioned the role of IL2RA, which may no longer be useful in patients with standard risk profiles and has been shown to be inferior to rATG in patients with higher immunological risk [4] . Recent data on early steroid avoidance regimens, however, suggest that there may still be a niche for IL2RA use.
Interest in early steroid withdrawal (stopping steroids on Days 5-10 post-transplantation) or steroid avoidance (no or only one steroid dose on the day of transplantation) regimens has increased following reports of the long-term safety of this approach and a possible reduction in post-transplant complications [13, 14] . This treatment method could, however, be considered as a form of high-risk transplantation, necessitating induction therapy in order to avoid unacceptably high early AR rates. This possibility was illustrated by the ATLAS study, in which 151 kidney transplant recipients received Tac with MPA without induction therapy and only a single perioperative dose of steroids [6] . These patients had a very high rate of biopsyproven acute rejection (BPAR) in the first 6 months after transplant (30.5%), compared with only 8.5% in the control arm receiving Tac, MPA and long-term steroids without induction. Although the high rejection rate did not seem to translate into worse outcomes at 3 years post-transplantation [15] , it is still a matter of concern. Transplant centres therefore generally include induction therapy in the immunosuppressive regimen when early steroid withdrawal is used.
Several studies, all using antibody induction therapy (mostly IL2RA), have investigated the most appropriate maintenance therapy in the context of steroid withdrawal. The FREEDOM study was an intercontinental trial that evaluated two steroidavoidance regimens [a steroid-free regimen (n ¼ 112) and a regimen of steroid withdrawal at Day 7 (n ¼ 116)], with basiliximab induction, enteric-coated MPA (1440 mg/day) and cyclosporine (CsA) [16] . Disappointingly, the 1-year BPAR rate was significantly higher in the steroid-free (32%) and steroidwithdrawal (26%) groups than in a control group in whom steroids were continued (15%). The severity of rejection in the steroid-free and steroid-withdrawal groups was generally mild, and 1-year graft survival and glomerular filtration rates (GFRs) were comparable to those in the control group. Nevertheless, this study suggested that treatment using IL2RA induction, CsA and MPA led to suboptimal control of rejection in the context of early steroid avoidance, even in a population with standard immunological risk (first transplant, 99% non-black). Studies using Tac, instead of CsA, showed better results. For example, in the European CARMEN study, a regimen of daclizumab, Tac and MPA and only one intraoperative bolus of steroids (n ¼ 260) was associated with equivalent rejection rates compared with a control group treated with Tac, MPA and maintenance steroids (6-month BPAR was 16.5% in both groups) [17] . In a trial conducted in the US by Woodle (n ¼ 191), BPAR rates were acceptable (BPAR 17.8% at 5 years, <10% at 6 months), although the BPAR rate was even lower in patients in the control group in whom steroids were continued (10.8% at 5 years, P ¼ 0.04) [18] . A recent systematic review and meta-analysis reported that early steroid avoidance was associated with an increased risk of rejection in trials in which CsA was used, but not in those in which Tac was used [13] . Regardless of whether CsA or Tac was used, this metaanalysis, as well as a more recent meta-analysis by the Cochrane collaboration, showed that steroid-avoidance regimens did not have a negative impact on graft or patient survival compared with controls [13, 14] .
It remains unclear, however, which induction agent is preferable in the context of early steroid withdrawal. Until recently, no randomized controlled trials (RCTs) had been conducted comparing IL2RA and rATG in this setting. The best approximation came from the study by Woodle et al. mentioned earlier [18] . Patients randomized to the early steroid withdrawal arm were treated with IL2RA or rATG according to centre preference. In a post hoc analysis, the risk of BPAR after early steroid withdrawal tended to be higher with IL2RA induction than with rATG (24.2% versus 14.4%; P ¼ 0.09). A multivariable analysis combining the results of this trial with those from three other prospective trials by the same investigators also showed a tendency towards a lower risk of AR when early steroid avoidance was preceded by rATG induction compared with no rATG [odds ratio 0.61, 95% confidence interval (CI) 0.30-1.27] [19] . Finally, a recent large retrospective analysis of national US registry data from kidney transplant recipients discharged on steroid-free maintenance immunosuppression showed a lower adjusted graft loss with rATG than with IL2RA induction (hazard ratio 1.19, 95% CI 1.01-1.39) [20] .
In December 2016, however, Thomusch et al. reported the results of the HARMONY study, a large multicentre RCT (n ¼ 615) conducted in Germany, in which renal transplant recipients were randomized 1:1:1 to receive IL2RA induction with Tac, MPA and steroid maintenance therapy (arm A), IL2RA induction and rapid corticosteroid withdrawal on Day 8 (arm B) or rATG induction and rapid corticosteroid withdrawal on Day 8 (arm C) [21] (Table 1 ). The BPAR rates were similar in all three arms (11.2% in arm A, 10.6% in arm B and 9.9% in arm C) and 1-year graft and patient survival rates were excellent and equivalent in all arms. Hence, although previous data had suggested that rATG may be superior to IL2RA in early steroidwithdrawal regimens, there were no differences in the HARMONY study. Results from the recently published ADVANCE study confirm the potential value of IL2RA induction in early steroid withdrawal protocols [22] . The ADVANCE study was an RCT (n ¼ 1081) in which two steroid minimization strategies [steroid withdrawal at Day 10 versus avoidance (i.e. only one intraoperative steroid dose)] were compared, with both arms receiving IL2RA induction, prolonged-release Tac and MPA therapy (Table 1) . Six-month BPAR rates were significantly lower in the 10-day steroid withdrawal arm than in the avoidance arm (8.7% versus 13.6%; P ¼ 0.006). Nonbiopsy-proven rejection rates were also reported, with a total of 18.2% (withdrawal) versus 25.9% (avoidance) (P ¼ 0.001) 'clinical' AR episodes. Because patients in the single-steroid dose arm required more rescue steroids, the cumulative steroid dose at 6 months was comparable between groups. Although the HARMONY and ADVANCE studies were conducted in two very similar European cohorts with standard immunological risk, the results in terms of rejection seem to be less favourable in the ADVANCE study, especially in the arm with only one perioperative steroid dose. What could be the explanation for these observations? First, we should consider how the BPAR and clinical AR rates were reported to avoid comparing 'apples with oranges'. In terms of BPAR rates, the HARMONY and ADVANCE studies both had good results, which were comparable to outcomes in other studies with contemporary Tac/ MPA/steroid maintenance regimens [7, 23] (Symphony: 12.3%, OSAKA: 10.3-16.1%). A possible criticism of the HARMONY study is that it did not report non-biopsy-proven AR rates. It is well known that many transplant centres report, in addition to cases of BPAR, a substantial number of cases of non-biopsyproven AR, which may reflect reluctance to perform a biopsy in some patients, or a low threshold for treatment in patients with doubtful or borderline rejection. For example, in the Tac arm of the Symphony study there was a 1-year clinical AR rate of 17.2% (whereas the BPAR rate was 12.3%), and in the OSAKA trial the three arms receiving Tac, MPA and steroids had clinical AR rates at 24 weeks ranging from 18.5% to 25.0% (whereas the BPAR rate was 10.3-16.1%) [7, 23] . The BPAR and clinical AR rates reported in the ADVANCE study may, therefore, not be so different from those achieved with current standard of care. Nevertheless, based on the ADVANCE study, one could conclude that it seems advisable to continue steroid therapy during the first week after transplantation, rather than stopping on Day 1. Additionally, it could be argued that the relatively low dose of MPA in the ADVANCE study (2 g/day for the first 14 days, 1 g/day thereafter) compared with that used in the HARMONY study (2 g/day throughout the first year) may have impacted on the risk of AR, suggesting that maintaining a high MPA dose may be preferable when using steroid withdrawal as the treatment regimen.
In summary, current data suggest that early steroidwithdrawal regimens do not increase the risk of AR when the remaining immunosuppressive therapy is sufficiently potent, which can be achieved using a combination of Tac, MPA 2 g/ day and antibody induction therapy, and preferably by continuing steroids for the first week after transplantation. Based on the most recent studies, IL2RA may be the induction agent of choice, because it appeared to be as effective as rATG and is generally associated with fewer adverse effects. Having said this, we should, however, be aware of the limitations of the current evidence. First, the HARMONY and ADVANCE studies were both conducted in Europe, in a predominantly white population with standard immunological risk. It cannot be ruled out that rATG is superior in patients with higher immunological risk, although these patients are usually not considered to be suitable candidates for steroid withdrawal. Secondly, the main advantage of early steroid-avoidance regimens, as supported by the HARMONY and ADVANCE studies, may be the reduction in post-transplant diabetes. The long-term consequences, 
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• Steroid-resistant BPAR: 3.8% however, remain unclear [14] . We have no definitive data to prove that steroid-avoidance improves long-term renal function or graft survival, nor that it decreases cardiovascular events or mortality [14, 24] . There are no data on the development of de novo donor-specific antibodies (dnDSA) or of chronic antibody-mediated rejection in this setting, which may theoretically have a counterproductive effect on long-term outcomes. The limited data also mean that we cannot exclude the possibility that rATG may eventually be shown to be preferable to IL2RA in early steroid-avoidance regimens if it is better at preventing the development of dnDSA [25] . Thirdly, if the main reason for choosing an early steroid-withdrawal regimen is the reduction in occurrence of post-transplant diabetes, it may make sense to choose a regimen that includes CsA instead of Tac, as the latter is known to be more diabetogenic. Although studies on early steroid withdrawal combined with CsA have shown suboptimal results [16, 26] , it is conceivable that a CsAbased regimen with withdrawal of steroids after 7 days, highdose MPA (e.g. 2500 mg/day) and antibody induction may also keep AR rates low and may perhaps be even better at preventing new onset diabetes mellitus after transplantation than Taccontaining regimens such as those used in the HARMONY and ADVANCE studies. This should be an area of future research. Again, possible differences in efficacy of rATG and IL2RA should be addressed in such settings. In summary, we believe that the 2009 KDIGO guidelines on induction therapy after kidney transplantation no longer reflect the current evidence in patients with standard and high immunological risk or in patients managed with early steroidwithdrawal regimens. In standard risk transplantation using Tac, MPA and maintenance steroids, induction therapy now seems redundant. In patients with high immunological risk, rATG is superior to IL2RA. However, there may still be a niche for IL2RA use in the context of early steroid-withdrawal regimens, at least in low-risk recipients maintained on Tac and MPA. Updated guidelines based on the latest evidence are eagerly awaited. Future studies should focus on a better understanding and quantification of immunological risk, which may help guide decisions regarding which induction therapy to choose, if any, for individual patients.
K E Y P O I N T S
• Antibody induction therapy may be redundant in standard-risk kidney transplant recipients maintained on Tac, MPA and steroids.
• rATG is preferable to IL2RA in kidney transplant recipients with high immunological risk.
• When choosing a regimen with early steroid withdrawal:
• Antibody induction therapy is advisable • IL2RA and rATG are equally effective in standard-risk recipients remaining on Tac and MPA. Given the balance of benefits and risks, IL2RA may be preferred over rATG in this setting.
• Maintenance therapy should be sufficiently potent:
• Steroid withdrawal after 7 days may be preferable to one preoperative dose.
• Consider to use Tac instead of CsA.
• Maintaining a high dose of MPA during the first year may be advisable.
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